The Selective Serotonin-2A Receptor Antagonist M100907 Reverses Behavioral Deficits in Dopamine Transporter Knockout Mice

Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter

Giros, B., Jaber, M., Jones, S. R., Wightman, R. M., & Caron, M. G. (1996) · Nature · doi:10.1038/379606a0 · Cited by 2,476 · see citing works

Molecular, pharmacological and functional diversity of 5-HT receptors

Hoyer, D., Hannon, J. P., & Martin, G. R. (2002) · Pharmacology Biochemistry and Behavior · doi:10.1016/s0091-3057(01)00746-8 · Cited by 1,869 · see citing works

Human studies of prepulse inhibition of startle: normal subjects, patient groups, and pharmacological studies

BRAFF, D. L., Geyer, M. A., & Swerdlow, N. R. (2001) · Psychopharmacology · doi:10.1007/s002130100810 · Cited by 1,701 · see citing works

Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review

Geyer, M. A., Krebs-Thomson, K., Braff, D. L., & Swerdlow, N. R. (2001) · Psychopharmacology · doi:10.1007/s002130100811 · Cited by 1,484 · see citing works

Reflex modification in the domain of startle: I. Some empirical findings and their implications for how the nervous system processes sensory input.

Hoffman, H. S., & Ison, J. R. (1980) · Psychological Review · doi:10.1037/0033-295x.87.2.175 · Cited by 780 · see citing works

The Role of Serotonin in Antipsychotic Drug Action

Meltzer, H. M. (1999) · Neuropsychopharmacology · doi:10.1016/s0893-133x(99)00046-9 · Cited by 664 · see citing works

Using an Animal Model of Deficient Sensorimotor Gating to Study the Pathophysiology and New Treatments of Schizophrenia

Swerdlow, N. R., & Geyer, M. A. (1998) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a033326 · Cited by 616 · see citing works

5-Hydroxytryptamine _2A serotonin receptors in the primate cerebral cortex: Possible site of action of hallucinogenic and antipsychotic drugs in pyramidal cell apical dendrites

Jakab, R. L., & Goldman-Rakic, P. S. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.2.735 · Cited by 536 · see citing works

Serotonin model of schizophrenia: emerging role of glutamate mechanisms

Aghajanian, G. (2000) · Brain Research Reviews · doi:10.1016/s0165-0173(99)00046-6 · Cited by 529 · see citing works

Serotonin and hallucinogens

Aghajanian, G. (1999) · Neuropsychopharmacology · doi:10.1016/s0893-133x(98)00135-3 · Cited by 371 · see citing works

Preclinical characterization of the potential of the putative atypical antipsychotic MDL 100,907 as a potent 5-HT2A antagonist with a favorable CNS safety profile.

Kehne, J. H., Baron, B. M., Carr, A. A., Chaney, S., Elands, J., Feldman, D. J., Frank, R. A., van Giersbergen, P. L. M., McCloskey, T. C., Johnson, M., et al. (1996) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)12956-x · Cited by 359 · see citing works

The role of endogenous sensitization in the pathophysiology of schizophrenia: implications from recent brain imaging studies.

Laruelle, M. (2000) · Brain research. Brain research reviews · doi:10.1016/s0165-0173(99)00054-5 · Cited by 347 · see citing works

5-HT1A and 5-HT2A Receptor mRNAs and Binding Site Densities Are Differentially Altered in Schizophrenia

Burnet, P. W. J. (1996) · Neuropsychopharmacology · doi:10.1016/s0893-133x(96)00053-x · Cited by 286 · see citing works

Prepulse Inhibition Deficits and Perseverative Motor Patterns in Dopamine Transporter Knock-Out Mice: Differential Effects of D1 and D2 Receptor Antagonists

Ralph, R. J., Paulus, M. P., Fumagalli, F., Caron, M. G., & Geyer, M. A. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-01-00305.2001 · Cited by 271 · see citing works

Sensorimotor gating deficits in bipolar disorder patients with acute psychotic mania

Perry, W., Minassian, A., Feifel, D., & Braff, D. L. (2001) · Biological Psychiatry · doi:10.1016/s0006-3223(01)01184-2 · Cited by 260 · see citing works

Characterization of the 5-HT2 receptor antagonist MDL 100907 as a putative atypical antipsychotic: behavioral, electrophysiological and neurochemical studies.

Sorensen, S. M., Kehne, J. H., Fadayel, G. M., Humphreys, T. M., Ketteler, H., Sullivan, C. K., Taylor, V. L., & Schmidt, C. J. (1993) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)38366-7 · Cited by 258 · see citing works

Association between schizophrenia and T102C polymorphism of the 5-hydroxytryptamine type 2a-receptor gene

Williams, J. H., Spurlock, G., McGuffin, P., Owen, M., Mallet, J. J., Nöthen, M. M., Gill, M., Aschauer, H. N., Nylander, P.-O., & Macciardi, F. M. (1996) · The Lancet · doi:10.1016/s0140-6736(96)90939-3 · Cited by 245 · see citing works

Functional hyperdopaminergia in dopamine transporter knock-out mice

Gainetdinov, R. R., Jones, S. R., & Caron, M. G. (1999) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00122-5 · Cited by 231 · see citing works

Behavioural disturbances associated with hyperdopaminergia in dopamine-transporter knockout mice

Spielewoy, C., Roubert, C., Hamon, M., Nosten‐Bertrand, M., Betancur, C., & Bruno Giros, A. (2000) · Behavioural Pharmacology · doi:10.1097/00008877-200006000-00011 · Cited by 228 · see citing works

5-HT2A and 5-HT2C/2B Receptor Subtypes Modulate Dopamine Release Induced in Vivo by Amphetamine and Morphine in Both the Rat Nucleus Accumbens and Striatum

Porras, G. (2002) · Neuropsychopharmacology · doi:10.1016/s0893-133x(01)00333-5 · Cited by 222 · see citing works

霊長類大脳皮質の5‐ヒドロキシトリプタミン2Aセロトニン受容体 錐体細胞先端樹状突起での幻覚剤及び抗精神病剤の作用部位

Jakab, R. L., & Goldman‐Rakic, P. S. (1998) · Cited by 182 · see citing works

Alterations in the cortical serotonergic system in schizophrenia: A postmortem study

Gurevich, E. V., & Joyce, J. N. (1997) · Biological Psychiatry · doi:10.1016/s0006-3223(97)00321-1 · Cited by 176 · see citing works

The Dopamine D₂, but not D₃or D₄, Receptor Subtype is Essential for the Disruption of Prepulse Inhibition Produced by Amphetamine in Mice

Ralph, R. J., Varty, G. B., Kelly, M. A., Wang, Y.-M., Caron, M. G., Rubinstein, M., Grandy, D. K., Low, M. J., & Geyer, M. A. (1999) · The Journal of Neuroscience · doi:10.1523/jneurosci.19-11-04627.1999 · Cited by 174 · see citing works

Role of Striatal Serotonin2A and Serotonin2C Receptor Subtypes in the Control of In Vivo Dopamine Outflow in the Rat Striatum

Lucas, G., & Spampinato, U. (2000) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2000.740693.x · Cited by 170 · see citing works

Glutamatergic modulation of hyperactivity in mice lacking the dopamine transporter

Gainetdinov, R. R., Mohn, A. R., Bohn, L., & Caron, M. G. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.191353298 · Cited by 168 · see citing works

Atypical antipsychotics: are some more atypical than others?

Remington, G. J., & Kapur, S. (2000) · Psychopharmacology · doi:10.1007/s002130050017 · Cited by 156 · see citing works

Classification and nomenclature of 5-HT receptors: a comment on current issues

Hoyer, D., & Martin, G. R. (1995) · Behavioural Brain Research · doi:10.1016/0166-4328(96)00109-x · Cited by 149 · see citing works

M100907, a Serotonin 5-HT2A Receptor Antagonist and Putative Antipsychotic, Blocks Dizocilpine-Induced Prepulse Inhibition Deficits in Sprague–Dawley and Wistar Rats

Varty, G. B., Bakshi, V. P., & Geyer, M. (1999) · Neuropsychopharmacology · doi:10.1016/s0893-133x(98)00072-4 · Cited by 137 · see citing works

5-HT2A receptor antagonism potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and inhibits that in the nucleus accumbens in a dose-dependent manner

Liégeois, J.-F., Ichikawa, J., & Meltzer, H. Y. (2002) · Brain Research · doi:10.1016/s0006-8993(02)02620-3 · Cited by 134 · see citing works

5-HT2 Receptor Antagonism Reduces Hyperactivity Induced by Amphetamine, Cocaine, and MK-801 But Not D1 Agonist C-APB

O‘Neill, M. F., Heron-Maxwell, C., & Shaw, G. (1999) · Pharmacology Biochemistry and Behavior · doi:10.1016/s0091-3057(98)00240-8 · Cited by 134 · see citing works

A temporal and spatial scaling hypothesis for the behavioral effects of psychostimulants

Paulus, M. P., & Geyer, M. A. (1991) · Psychopharmacology · doi:10.1007/bf02244547 · Cited by 134 · see citing works

Antagonism of 5-Hydroxytryptamine2A Receptors Attenuates the Behavioral Effects of Cocaine in Rats

McMahon, L. R., & Cunningham, K. A. (2001) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)29546-x · Cited by 133 · see citing works

M100,907, a selective 5-HT2A antagonist, attenuates dopamine release in the rat medial prefrontal cortex

Pehek, E. A., McFarlane, H. G., Maguschak, K. A., Price, B., & Pluto, C. P. (2001) · Brain Research · doi:10.1016/s0006-8993(00)03004-3 · Cited by 131 · see citing works

Monoamine transporter pharmacology and mutant mice

Gainetdinov, R. R., Sotnikova, T. D., & Caron, M. G. (2002) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(02)02044-8 · Cited by 126 · see citing works

Electrophysiological, biochemical and behavioral evidence for 5-HT2 and 5-HT3 mediated control of dopaminergic function

Palfreyman, M. G., Schmidt, C. J., Sorensen, S. M., Dudley, M. W., Kehne, J. H., Moser, P. C., Gittos, M. W., & Carr, A. A. (1993) · Psychopharmacology · doi:10.1007/bf02245008 · Cited by 125 · see citing works

A systematic review of the use of atypical antipsychotics in autism

Barnard, L., Young, A. H., Pearson, J., Geddes, J. R., & O'Brien, G. (2002) · Journal of Psychopharmacology · doi:10.1177/026988110201600113 · Cited by 124 · see citing works

Serotonin 1B receptor modulation of startle reactivity, habituation, and prepulse inhibition in wild-type and serotonin 1B knockout mice

Dulawa, S. C., Hen, R., Scearce-Levie, K. A., & Geyer, M. A. (1997) · Psychopharmacology · doi:10.1007/s002130050328 · Cited by 122 · see citing works

5-HT modulation of auditory and visual sensorimotor gating: II. Effects of the 5-HT2A antagonist MDL 100,907 on disruption of sound and light prepulse inhibition produced by 5-HT agonists in Wistar rats

Padich, R. A., McCloskey, T. C., & Kehne, J. H. (1996) · Psychopharmacology · doi:10.1007/bf02245610 · Cited by 119 · see citing works

DOI disrupts prepulse inhibition of startle in rats via 5-HT2A receptors in the ventral pallidum

Sipes, T. E., & Geyer, M. A. (1997) · Brain Research · doi:10.1016/s0006-8993(97)00316-8 · Cited by 118 · see citing works

Reversal of amphetamine-induced behaviours by MDL 100,907, a selective 5-HT2A antagonist

Moser, P. C., Moran, P. M., Frank, R. A., & Kehne, J. H. (1995) · Behavioural Brain Research · doi:10.1016/0166-4328(96)00090-3 · Cited by 111 · see citing works

Decreased Serotonin 2A Receptor Densities in Neuroleptic-Naive Patients With Schizophrenia: A PET Study Using [18F]Setoperone

Ngan, E. T. C., Yatham, L. N., Ruth, T. J., & Liddle, P. F. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.6.1016 · Cited by 104 · see citing works

Serotonin 5-HT1A receptor expression is selectively enhanced in the striosomal compartment of chronic parkinsonian monkeys

Frechilla, D., Cobreros, A., Saldise, L., Moratalla, R., Insausti, R., Luquín, M. R., & R�o, J. D. (2001) · Synapse · doi:10.1002/1098-2396(20010315)39:4 · Cited by 103 · see citing works

The selective 5-HT2a receptor antagonist MDL 100,907 counteracts the psychomotor stimulation ensuing manipulations with monoaminergic, glutamatergic or muscarinic neurotransmission in the mouse ? implications for psychosis

Carlsson, M. L. (1995) · Journal of Neural Transmission · doi:10.1007/bf01276460 · Cited by 86 · see citing works

Behavioral Studies of Hallucinogenic Drugs in Animals: Implications for Schizophrenia Research

Geyer, M. A. (1998) · Pharmacopsychiatry · doi:10.1055/s-2007-979350 · Cited by 80 · see citing works

The 5-HT2A receptor antagonist M100907 is more effective in counteracting NMDA antagonist- than dopamine agonist-induced hyperactivity in mice

Carlsson, M. L., Martin, P., Nilsson, M., Sorensen, S. M., Carlsson, A., Waters, N., & Waters, N. (1999) · Journal of Neural Transmission · doi:10.1007/s007020050144 · Cited by 78 · see citing works

M-100907 (Aventis).

de Paulis, T. (2001) · PubMed · Cited by 71 · see citing works

High 5HT 2A receptor occupancy in M100907-treated schizophrenic patients

Talvik, M., Nyberg, S., Nordström, A., Ito, H., Halldin, C., Brunner, F., & Farde, L. (2000) · Psychopharmacology · doi:10.1007/s002130050069 · Cited by 61 · see citing works

Polymorphism of the serotonin-2A receptor gene (HTR2A) associated with childhood attention deficit hyperactivity disorder (ADHD) in adult women with seasonal affective disorder.

Levitan, R., Masellis, M., Basile, V., Lam, R. W., Jain, U., Kaplan, A. S., Kennedy, S. H., Siegel, G., Walker, M., Vaccarino, F., et al. (2002) · Journal of Affective Disorders · doi:10.1016/s0165-0327(01)00372-x · Cited by 57 · see citing works

Antagonism at 5-HT2A receptors potentiates the effect of haloperidol in a conditioned avoidance response task in rats

Wadenberg, M.-L. G., Browning, J. L., Young, K. A., & Hicks, P. B. (2001) · Pharmacology Biochemistry and Behavior · doi:10.1016/s0091-3057(00)00483-4 · Cited by 48 · see citing works

Positron Emission Tomographic Analysis of Dose-Dependent MDL 100,907 Binding to 5-Hydroxytryptamine-2A Receptors in the Human Brain

Andrée, B., Nyberg, S., Ito, H., Ginovart, N., Brunner, F., Jaquet, F., Halldin, C., & Farde, L. (1998) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199808000-00012 · Cited by 45 · see citing works

Effects of atypical antipsychotic drugs on dopamine output in the shell and core of the nucleus accumbens: role of 5-HT(2A) and alpha(1)-adrenoceptor antagonism.

Marcus, M., Nomikos, G., & Svensson, T. (2000) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(00)00077-8 · Cited by 42 · see citing works

5-HT2A antagonists in psychiatric disorders.

Angelis, L. D. (2002) · PubMed · Cited by 41 · see citing works

Enhancement of antipsychoticlike properties of raclopride in rats using the selective serotonin2A receptor antagonist MDL 100,907

Wadenberg, M.-L. G., Hicks, P. B., Richter, J. T., & Young, K. A. (1998) · Biological Psychiatry · doi:10.1016/s0006-3223(97)00424-1 · Cited by 39 · see citing works

Pharmacological and molecular targets in the search for novel antipsychotics

Scatton, B., & Sanger, D. J. (2000) · Behavioural Pharmacology · doi:10.1097/00008877-200006000-00008 · Cited by 39 · see citing works

Chromosome 22q11 deletions are not found in autistic patients identified using strict diagnostic criteria

Ogilvie, C. M., Moore, J., Daker, M. G., Palferman, S., Docherty, Z., & IMGSAC (2000) · American Journal of Medical Genetics · doi:10.1002/(sici)1096-8628(20000207)96:1 · Cited by 33 · see citing works

The Role of Positron Emission Tomography in the Drug Development of M100907, a Putative Antipsychotic with a Novel Mechanism of Action

Offord, S. J., Wong, D. F., & Nyberg, S. (1999) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1999.tb05933.x · Cited by 27 · see citing works

Pharmacologic mechanisms of serotonergic regulation of dopamine neurotransmission

Alex, K. D., & Pehek, E. A. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2006.08.004 · Cited by 658 · see citing works

Realistic expectations of prepulse inhibition in translational models for schizophrenia research

Swerdlow, N. R., Weber, M., Qu, Y., Light, G. A., & Braff, D. L. (2008) · Psychopharmacology · doi:10.1007/s00213-008-1072-4 · Cited by 529 · see citing works

Schizophrenia-Relevant Behavioral Testing in Rodent Models: A Uniquely Human Disorder?

Powell, C. M., & Miyakawa, T. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.05.008 · Cited by 368 · see citing works

Reward circuitry dysfunction in psychiatric and neurodevelopmental disorders and genetic syndromes: animal models and clinical findings

Dichter, G. S., Damiano, C. A., & Allen, J. A. (2012) · Journal of Neurodevelopmental Disorders · doi:10.1186/1866-1955-4-19 · Cited by 299 · see citing works

Animal models of attention-deficit hyperactivity disorder

Russell, V. A., Sagvolden, T., & Johansen, E. B. (2005) · Behavioral and Brain Functions · doi:10.1186/1744-9081-1-9 · Cited by 234 · see citing works

Prepulse inhibition and genetic mouse models of schizophrenia

Powell, S. B., Zhou, X., & Geyer, M. A. (2009) · Behavioural Brain Research · doi:10.1016/j.bbr.2009.04.021 · Cited by 218 · see citing works

Evidence for the Preferential Involvement of 5-HT2A Serotonin Receptors in Stress- and Drug-Induced Dopamine Release in the Rat Medial Prefrontal Cortex

Pehek, E. A., Nocjar, C., Roth, B., Byrd, T. A., & Mabrouk, O. (2006) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300819 · Cited by 212 · see citing works

Trace amine-associated receptor 1—Family archetype or iconoclast?

Grandy, D. K. (2007) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2007.06.007 · Cited by 196 · see citing works

Overview of Animal Models of Attention Deficit Hyperactivity Disorder (ADHD)

Russell, V. A. (2011) · Current Protocols in Neuroscience · doi:10.1002/0471142301.ns0935s54 · Cited by 176 · see citing works

Exploration of 19 serotoninergic candidate genes in adults and children with attention-deficit/hyperactivity disorder identifies association for 5HT2A, DDC and MAOB

Marta Ribasés, A., Ramos‐Quiroga, J. A., Amaia Hervas, G., Bosch, R., Bielsa, A., Gastaminza, X., Artigas-Pallarés, J., Rodriguez-Ben, S., Estivill, X., Casas, M., et al. (2007) · Molecular Psychiatry · doi:10.1038/sj.mp.4002100 · Cited by 154 · see citing works

Neurobiology of animal models of attention-deficit hyperactivity disorder

Russell, V. A. (2006) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2006.12.005 · Cited by 145 · see citing works

Does serotonin deficit mediate susceptibility to ADHD?

Banerjee, E., & Nandagopal, K. (2015) · Neurochemistry International · doi:10.1016/j.neuint.2015.02.001 · Cited by 125 · see citing works

Membrane transporters as mediators of synaptic dopamine dynamics: implications for disease

Lohr, K. M., Masoud, S. T., Salahpour, A., & Miller, G. W. (2016) · European Journal of Neuroscience · doi:10.1111/ejn.13357 · Cited by 124 · see citing works

A reverse-translational approach to bipolar disorder: Rodent and human studies in the Behavioral Pattern Monitor

Young, J. W., Minassian, A., Paulus, M. P., Geyer, M. A., & Perry, W. (2007) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2007.05.009 · Cited by 122 · see citing works

Genetic Mouse Models of Schizophrenia: From Hypothesis-Based To Susceptibility Gene-Based Models

Chen, J., Lipska, B. K., & Weinberger, D. R. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.02.024 · Cited by 108 · see citing works

Review of Rodent Models of Attention Deficit Hyperactivity Disorder

Regan, S. L., Williams, M. T., & Vorhees, C. (2021) · Neuroscience and Biobehavioral Reviews · doi:10.1016/j.neubiorev.2021.11.041 · Cited by 96 · see citing works

Psychostimulant withdrawal as an inducing condition in animal models of depression

Barr, A. M., & Markou, A. (2005) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2005.03.012 · Cited by 107 · see citing works

Role of the serotonin system in ADHD: treatment implications

Oades, R. D. (2007) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.7.10.1357 · Cited by 92 · see citing works

“Selective” serotonin 5-HT2A receptor antagonists

Casey, A. B., Cui, M., Booth, R. G., & Canal, C. E. (2022) · Biochemical Pharmacology · doi:10.1016/j.bcp.2022.115028 · Cited by 94 · see citing works

Psychostimulant-Induced Attenuation of Hyperactivity and Prepulse Inhibition Deficits inAdcyap1-Deficient Mice

Tanaka, K., Shintani, N., Hashimoto, H., Kawagishi, N., Ago, Y., Matsuda, T., Hashimoto, R., Kunugi, H., Yamamoto, A., Kawaguchi, C., et al. (2006) · Journal of Neuroscience · doi:10.1523/jneurosci.4376-05.2006 · Cited by 85 · see citing works

Dopamine transporter mutant animals: a translational perspective

Efimova, E. V., Gainetdinov, R. R., Budygin, E. A., & Sotnikova, T. D. (2016) · Journal of Neurogenetics · doi:10.3109/01677063.2016.1144751 · Cited by 83 · see citing works

Transgenic mouse models for ADHD

Leo, D., & Gainetdinov, R. (2013) · Cell and Tissue Research · doi:10.1007/s00441-013-1639-1 · Cited by 74 · see citing works

Understanding autism and other neurodevelopmental disorders through experimental translational neurobehavioral models

Homberg, J. R., Kyzar, E. J., Nguyen, M., Norton, W., Pittman, J. T., Poudel, M. K., Gaikwad, S., Nakamura, S., Koshiba, M., Yamanouchi, H., et al. (2016) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2016.03.013 · Cited by 83 · see citing works

Alterations of dopamine and serotonin transmission in schizophrenia

Remington, G. (2008) · Progress in brain research · doi:10.1016/s0079-6123(08)00906-0 · Cited by 81 · see citing works

Norepinephrine Transporter Blockade can Normalize the Prepulse Inhibition Deficits Found in Dopamine Transporter Knockout Mice

Yamashita, M., Fukushima, S., Shen, H.-W., Hall, F. S., Uhl, G. R., Numachi, Y., Kobayashi, H., & Sora, I. (2006) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301009 · Cited by 77 · see citing works

Gene-dose dependent effects of methamphetamine on interval timing in dopamine-transporter knockout mice

Meck, W. H., Cheng, R., MacDonald, C. J., Gainetdinov, R. R., Caron, M. G., & Çevik, M. Ö. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.01.042 · Cited by 76 · see citing works

Attention-deficit/hyperactive disorder updates

Kessi, M., Duan, H., Xiong, J., Chen, B., He, F., Yang, L., Ma, Y., Bamgbade, O. A., Peng, J., & Yin, F. (2022) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2022.925049 · Cited by 82 · see citing works

Dopamine transporter mutant mice in experimental neuropharmacology

Gainetdinov, R. R. (2007) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-007-0216-0 · Cited by 75 · see citing works

Dopamine transporter‐dependent and ‐independent actions of trace amine β‐phenylethylamine

Sotnikova, T. D., Budygin, E. A., Jones, S. R., Dykstra, L., Caron, M. G., & Gainetdinov, R. R. (2004) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2004.02721.x · Cited by 74 · see citing works

The dopamine transporter role in psychiatric phenotypes

Salatino‐Oliveira, A., Rohde, L. A., & Hutz, M. H. (2017) · American Journal of Medical Genetics Part B Neuropsychiatric Genetics · doi:10.1002/ajmg.b.32578 · Cited by 72 · see citing works

Implications of genome wide association studies for addiction: Are our a priori assumptions all wrong?

Hall, F. S., Drgonová, J., Jain, S., & Uhl, G. R. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.07.006 · Cited by 71 · see citing works

Role of the serotonin 5-HT2A receptor in the hyperlocomotive and hyperthermic effects of (+)-3,4-methylenedioxymethamphetamine

Herin, D. V., Liu, S., Ullrich, T., Rice, K. C., & Cunningham, K. A. (2004) · Psychopharmacology · doi:10.1007/s00213-004-2030-4 · Cited by 69 · see citing works

Cross-species assessments of motor and exploratory behavior related to bipolar disorder

Henry, B. L., Minassian, A., Young, J. W., Paulus, M. P., Geyer, M. A., & Perry, W. (2010) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2010.04.002 · Cited by 65 · see citing works

Heterozygous reeler mice exhibit alterations in sensorimotor gating but not presynaptic proteins

Barr, A. M., Fish, K. N., Markou, A., & Honer, W. G. (2008) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2008.06233.x · Cited by 60 · see citing works

Atypical antipsychotics clozapine and quetiapine attenuate prepulse inhibition deficits in dopamine transporter knockout mice

Powell, S. B., Young, J. W., Ong, J. C., Caron, M. G., & Geyer, M. A. (2008) · Behavioural Pharmacology · doi:10.1097/fbp.0b013e32830dc110 · Cited by 57 · see citing works

Nicotine Improves Cognitive Deficits of Dopamine Transporter Knockout Mice without Long-Term Tolerance

Weiss, S., Nosten‐Bertrand, M., McIntosh, J. M., Bruno Giros, A., & Martres, M. (2007) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301385 · Cited by 54 · see citing works

Animal models of tic disorders: A translational perspective

Godar, S. C., Mosher, L. J., Giovanni, G. D., & Bortolato, M. (2014) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2014.09.008 · Cited by 54 · see citing works

Iloperidone reduces sensorimotor gating deficits in pharmacological models, but not a developmental model, of disrupted prepulse inhibition in rats

Barr, A. M., Powell, S. B., Markou, A., & Geyer, M. A. (2006) · Neuropharmacology · doi:10.1016/j.neuropharm.2006.04.004 · Cited by 49 · see citing works

Alterations in dopamine system and in its connectivity with serotonin in a rat model of Alzheimer’s disease

Ceyzériat, K., Gloria, Y., Tsartsalis, S., Fossey, C., Cailly, T., Fabis, F., Millet, P., & Tournier, B. B. (2021) · Brain Communications · doi:10.1093/braincomms/fcab029 · Cited by 43 · see citing works

An evaluation of the serotonin system and perseverative, compulsive, stereotypical, and hyperactive behaviors in dopamine transporter (DAT) knockout mice

Fox, M. A., Panessiti, M., Hall, F. S., Uhl, G. R., & Murphy, D. L. (2013) · Psychopharmacology · doi:10.1007/s00213-013-2988-x · Cited by 48 · see citing works

MDMA ?ecstasy? alters hyperactive and perseverative behaviors in dopamine transporter knockout mice

Powell, S. B., Masten, V. L., Paulus, M. P., Gainetdinov, R. R., Caron, M. G., & Geyer, M. A. (2004) · Psychopharmacology · doi:10.1007/s00213-003-1765-7 · Cited by 43 · see citing works

Functional alterations of nicotinic neurotransmission in dopamine transporter knock-out mice

Weiss, S., Tzavara, E. T., Davis, R. J., Nomikos, G. G., McIntosh, J. M., Giros, B., & Martres, M. (2007) · Neuropharmacology · doi:10.1016/j.neuropharm.2007.02.002 · Cited by 42 · see citing works

Rodent Models of ADHD

Fan, X., Bruno, K. J., & Hess, E. J. (2011) · Current topics in behavioral neurosciences · doi:10.1007/7854_2011_121 · Cited by 42 · see citing works

Alterations of GABAergic and dopaminergic systems in mutant mice with disruption of exons 2 and 3 of the Disc1 gene

NAKAI, T., Nagai, T., Wang, R., Yamada, S., Kuroda, K., Kaibuchi, K., & Yamada, K. (2014) · Neurochemistry International · doi:10.1016/j.neuint.2014.06.009 · Cited by 41 · see citing works

Dissociations between interval timing and intertemporal choice following administration of fluoxetine, cocaine, or methamphetamine

Heilbronner, S. R., & Meck, W. H. (2013) · Behavioural Processes · doi:10.1016/j.beproc.2013.09.013 · Cited by 38 · see citing works

Transgenic mice in the study of drug addiction and the effects of psychostimulant drugs

Sora, I., Li, B., Igari, M., Hall, F. S., & Ikeda, K. (2010) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2009.05276.x · Cited by 38 · see citing works

Behavioral Animal Models of Antipsychotic Drug Actions

Peleg‐Raibstein, D., Feldon, J., & Meyer, U. (2012) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-25761-2_14 · Cited by 37 · see citing works

Animal Models of ADHD

Bari, A., & Robbins, T. W. (2011) · Current topics in behavioral neurosciences · doi:10.1007/7854_2010_102 · Cited by 35 · see citing works

Activation of nucleus tractus solitarius 5‐HT2Abut not other 5‐HT2receptor subtypes inhibits the sympathetic activity in rats

Comet, M. ‐., Bernard, J., Hamon, M., Laguzzi, R. F., & Sévoz‐Couche, C. (2007) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2007.05673.x · Cited by 34 · see citing works

Abnormally persistent latent inhibition induced by MK801 is reversed by risperidone and by positive modulators of NMDA receptor function: differential efficacy depending on the stage of the task at which they are administered

Gaisler‐Salomon, I., Diamant, L., Rubin, C., & Weiner, I. (2007) · Psychopharmacology · doi:10.1007/s00213-007-0960-3 · Cited by 34 · see citing works

Annual Research Review: Transgenic mouse models of childhood‐onset psychiatric disorders

Robertson, H. R., & Feng, G. (2011) · Journal of Child Psychology and Psychiatry · doi:10.1111/j.1469-7610.2011.02380.x · Cited by 33 · see citing works

Cerebellar 5HT-2A receptor mediates stress-induced onset of dystonia

Kim, J. E., Chae, S., Kim, S., Jung, Y., Kang, M., Heo, W. D., & Kim, D. (2021) · Science Advances · doi:10.1126/sciadv.abb5735 · Cited by 36 · see citing works

Selective effects of typical antipsychotic drugs on SNAP-25 and synaptophysin in the hippocampal trisynaptic pathway

Barr, A. M., Young, C. E., Phillips, A. G., & Honer, W. G. (2005) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145705006000 · Cited by 31 · see citing works

Reprint of “Neurobiology of animal models of attention-deficit hyperactivity disorder”

Russell, V. A. (2007) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2006.12.020 · Cited by 29 · see citing works

Effects of Atomoxetine on Hyper-Locomotive Activity of the Prenatally Valproate-Exposed Rat Offspring

Choi, C. S., Hong, M., Kim, K. C., Kim, J., Yang, S. M., Seung, H., Ko, M. J., Choi, D., You, J. S., Shin, C. Y., et al. (2014) · Biomolecules & Therapeutics · doi:10.4062/biomolther.10.4062/biomolther.2014.027 · Cited by 27 · see citing works

From neurons to brain networks, pharmacodynamics of stimulant medication for ADHD

Parlatini, V., Bellato, A., Murphy, D., & Cortese, S. (2024) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2024.105841 · Cited by 26 · see citing works

Dopamine Transporter Deficient Rodents: Perspectives and Limitations for Neuroscience

Savchenko, A. A., Targa, G., Fesenko, Z. S., Leo, D., Gainetdinov, R. R., & Sukhanov, I. (2023) · Biomolecules · doi:10.3390/biom13050806 · Cited by 29 · see citing works

The reelin receptors VLDLR and ApoER2 regulate sensorimotor gating in mice

Barr, A. M., Fish, K. N., & Markou, A. (2007) · Neuropharmacology · doi:10.1016/j.neuropharm.2006.11.011 · Cited by 25 · see citing works

Strengths and limitations of genetic models of ADHD

Gainetdinov, R. R. (2010) · ADHD Attention Deficit and Hyperactivity Disorders · doi:10.1007/s12402-010-0021-3 · Cited by 24 · see citing works

Research Domain Criteria versus DSM V: How does this debate affect attempts to model corticostriatal dysfunction in animals?

Young, J. W., Winstanley, C. A., Brady, A. M., & Hall, F. S. (2016) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2016.10.029 · Cited by 24 · see citing works

Using affect‐modulated startle to study phenotypes of pediatric bipolar disorder

Rich, B. A., Bhangoo, R. K., Vinton, D. T., Berghorst, L. H., Dickstein, D. P., Grillon, C., Davidson, R. J., & Leibenluft, E. (2005) · Bipolar Disorders · doi:10.1111/j.1399-5618.2005.00265.x · Cited by 24 · see citing works

A translational research approach to poor treatment response in patients with schizophrenia: clozapine–antipsychotic polypharmacy

Honer, W. G., Procyshyn, R. M., Chen, E. Y. H., MacEwan, G. W., & Barr, A. M. (2009) · Journal of Psychiatry and Neuroscience · doi:10.1139/jpn.0954 · Cited by 23 · see citing works

Mechanism Exploration of Arylpiperazine Derivatives Targeting the 5-HT2A Receptor by In Silico Methods

Lin, F., Li, F., Wang, C., Wang, J., Yang, Y., Yang, L., & Li, Y. (2017) · Molecules · doi:10.3390/molecules22071064 · Cited by 23 · see citing works

The α2 adrenergic receptor antagonist idazoxan, but not the serotonin-2A receptor antagonist M100907, partially attenuated reward deficits associated with nicotine, but not amphetamine, withdrawal in rats

Semenova, S., & Markou, A. (2010) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2010.05.003 · Cited by 22 · see citing works

The mGluR2/3 Agonist LY379268 Blocks the Effects of GLT-1 Upregulation on Prepulse Inhibition of the Startle Reflex in Adult Rats

Bellesi, M., & Conti, F. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2009.225 · Cited by 22 · see citing works

GBR 12909 administration as an animal model of bipolar mania: time course of behavioral, brain oxidative alterations and effect of mood stabilizing drugs

Queiroz, A. I. G., de Araújo, M. M., Araújo, T. D. S., de Souza, G. C., Cavalcante, L. M., Machado, M. D. J. S., de Lucena, D. F., Quevedo, J., & Macêdo, D. S. (2015) · Metabolic Brain Disease · doi:10.1007/s11011-015-9697-6 · Cited by 22 · see citing works

If waking and dreaming consciousness became de-differentiated, would schizophrenia result?

Llewellyn, S. (2011) · Consciousness and Cognition · doi:10.1016/j.concog.2011.03.022 · Cited by 21 · see citing works

Altered performance of reelin-receptor ApoER2 deficient mice on spatial tasks using the Barnes maze.

Barr, A. M., MacLaurin, S. A., Semenova, S., Fish, K. N., & Markou, A. (2007) · Behavioral Neuroscience · doi:10.1037/0735-7044.121.5.1101 · Cited by 18 · see citing works

The Role of the Dopamine Transporter in the Effects of Amphetamine on Sleep and Sleep Architecture in Drosophila

Karam, C. S., Williams, B. L., Jones, S. K., & Javitch, J. A. (2021) · Neurochemical Research · doi:10.1007/s11064-021-03275-4 · Cited by 17 · see citing works

Effects of Atomoxetine on Motor and Cognitive Behaviors and Brain Electrophysiological Activity of Dopamine Transporter Knockout Rats

Ptukha, M. A., Fesenko, Z. S., Belskaya, A. D., Gromova, A. A., Pelevin, A., Kurzina, N. P., Gainetdinov, R. R., & Volnova, A. B. (2022) · Biomolecules · doi:10.3390/biom12101484 · Cited by 15 · see citing works

Novelty-induced activity-regulated cytoskeletal-associated protein (Arc) expression in frontal cortex requires serotonin 2A receptor activation

Santini, M. A., Klein, A. B., El-Sayed, M., Ratner, C., Knudsen, G. M., Mikkelsen, J. D., & Aznar, S. (2011) · Neuroscience · doi:10.1016/j.neuroscience.2011.05.048 · Cited by 15 · see citing works

Antimanic activity of minocycline in a GBR12909-induced model of mania in mice: Possible role of antioxidant and neurotrophic mechanisms

Queiroz, A. I. G., Filho, A. J. M. C., Araújo, T. D. S., Lima, C. N. D. C., Machado, M. D. J. S., Carvalho, A. F., Vasconcelos, S. M. M., de Lucena, D. F., Quevedo, J., & Macêdo, D. S. (2017) · Journal of Affective Disorders · doi:10.1016/j.jad.2017.07.053 · Cited by 15 · see citing works

New therapeutic potential for psychoactive natural products

Prevatt‐Smith, K. M., & Prisinzano, T. E. (2009) · Natural Product Reports · doi:10.1039/b912196j · Cited by 14 · see citing works

Hyperactive behavioral phenotypes and an altered brain monoaminergic state in male offspring mice with perinatal hypothyroidism

Umezu, T., Kita, T., & Morita, M. (2019) · Toxicology Reports · doi:10.1016/j.toxrep.2019.10.005 · Cited by 13 · see citing works

Involvement of serotoninergic 5-HT1A/2A, alpha-adrenergic and dopaminergic D1 receptors in St. John's wort-induced prepulse inhibition deficit: A possible role of hyperforin

Tadros, M. G., Mohamed, M. R., Youssef, A. M., Sabry, G. M., Sabry, N. A., & Khalifa, A. E. (2008) · Behavioural Brain Research · doi:10.1016/j.bbr.2008.12.015 · Cited by 13 · see citing works

Methylphenidate and Guanfacine Ameliorate ADHD-Like Phenotypes in Fez1-Deficient Mice

Sumitomo, A., Saka, A., Ueta, K., Horike, K., Hirai, K., Gamo, N. J., Hikida, T., Nakayama, K. I., Sawa, A., Sakurai, T., et al. (2017) · Complex Psychiatry · doi:10.1159/000488081 · Cited by 12 · see citing works

Prepulse inhibition is different in two inbred mouse strains (CPB-K and BALB/cJ) with different hippocampal NMDA receptor densities

Wolf, R. J., Dobrowolny, H., Matzke, K., Paelchen, K., Bogerts, B., & Schwegler, H. (2005) · Behavioural Brain Research · doi:10.1016/j.bbr.2005.07.027 · Cited by 12 · see citing works

Effects of combined 5-HT2A and cannabinoid receptor modulation on a schizophrenia-related prepulse inhibition deficit in mice

Marques, A. M., Macena, M. V., Cardoso, A. R., Hammes, C. S. O., Pinheiro, F. M. L., Castro, N. G., & Neves, G. A. (2020) · Psychopharmacology · doi:10.1007/s00213-020-05485-0 · Cited by 10 · see citing works

p-Hydroxyamphetamine causes prepulse inhibition disruption in mice: Contribution of serotonin neurotransmission

Onogi, H., Nakagawasai, O., Sato, A., Mitazaki, S., Nakaya, K., Watanabe, K., Yaoita, F., Tan–No, K., Arai, Y., Kikuchi, T., et al. (2011) · Behavioural Brain Research · doi:10.1016/j.bbr.2011.06.002 · Cited by 9 · see citing works

Mutant Mouse Models in Evaluating Novel Approaches to Antipsychotic Treatment

O’Tuathaigh, C. M. P., Desbonnet, L., & Waddington, J. L. (2012) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-25758-2_5 · Cited by 8 · see citing works

Revisiting the Role of Serotonin in Attention-Deficit Hyperactivity Disorder: New Insights from Preclinical and Clinical Studies

Solomon, M. B., Yegla, B., Newcorn, J. H., Maletic, V., Rubin, J. S., & Robbins, T. W. (2025) · Clinical Drug Investigation · doi:10.1007/s40261-025-01473-4 · Cited by 8 · see citing works

Role of serotonin in the neurobiology of attention-deficit/hyperactivity disorder: a systematic literature review

Faraone, S. V., Ward, C. L., Boucher, M., Elbekai, R. H., & Brunner, E. (2025) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2025.2552324 · Cited by 8 · see citing works

Knocking Out the Dopamine Reuptake Transporter (DAT) Does not Change the Baseline Brain Arachidonic Acid Signal in the Mouse

Ramadan, E., Chang, L., Chen, M., Ma, K., Hall, F. S., Uhl, G. R., Rapoport, S. I., & Basselin, M. (2012) · International Journal of Neuroscience · doi:10.3109/00207454.2012.665972 · Cited by 5 · see citing works

Attention-deficit hyperactivity disorder

Sotnikova, T. D., & Gainetdinov, R. R. (2014) · Cambridge University Press eBooks · doi:10.1017/cbo9781107360556.015 · Cited by 8 · see citing works

The Ins and Outs of Dopamine Transporter Gene Manipulation: In Vivo Models of DAT Dysfunction

Stewart, A., & Blakely, R. (2025) · Advances in neurobiology · doi:10.1007/978-3-031-96364-3_10 · Cited by 3 · see citing works

Differential effects of the antidepressant mirtazapine on amphetamine- and dizocilpine-induced PPI deficits

Larrauri, J. A., & Levin, E. D. (2012) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2012.03.010 · Cited by 3 · see citing works

THEORETICAL AND INSILCO PHARMACOKINETIC INVESTIGATIONS ON SOME PHENYL PIPERIDINE DERIVATIVES AS NOVEL ANTIDEPRESSANT AGENTS

Olasupo, S. B., Uzairu, A., Shallangwa, G. A., & Uba, S. (2020) · The Journal of Engineering and Exact Sciences · doi:10.18540/jcecvl6iss2pp0107-0128 · Cited by 2 · see citing works

The metabolism of indoleamines

Tricklebank, M. D., & Martins, D. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-813323-1.00001-3 · Cited by 1 · see citing works

[Microcirculation end effect of detralex in patients with chronic venous insufficiency of the lower extremities].

Sirotin, B. Z., & Жмеренецкий, К. В. (2003) · PubMed · Cited by 1 · see citing works

The role of dopamine D2 and neuregulin-1 receptors in schizophrenia relevant phenotypes of cognition, attention and memory

Mathur, N. (2012) · Nottingham ePrints (University of Nottingham) · Cited by 1 · see citing works

Psychopathology of psychosis: Towards integration from an idealist perspective

Behrendt, R., & Young, C. C. (2004) · Behavioral and Brain Sciences · doi:10.1017/s0140525x04440187

Étude du rôle de la dopamine et de la sérotonine dans l’effet atténuateur des antipsychotiques et de l’OSU-6162 sur la récompense induite par la stimulation du faisceau médian prosencéphalique chez le rongeur

Benaliouad, F. (2009) · doi:10.71781/30069

Social dysfunction and mental retardation

Pietropaolo, S., Sluyter, F., & Crusio, W. E. (2014) · Cambridge University Press eBooks · doi:10.1017/cbo9781107360556.010

Monoaminergic Approaches for Treatment of Schizophrenia

Rotella, D. P. (2012) · Royal Society of Chemistry eBooks · doi:10.1039/9781849734943-00035

Cocaine-related disorders

Hall, F. S., & Sora, I. (2014) · Cambridge University Press eBooks · doi:10.1017/cbo9781107360556.028

Papel de receptores monoaminérgicos, colinérgicos e glutamatérgicos no efeito pro-mnéstico de Ptychopetalum olacoides Bentham (Olacaceae).

Saúde, B. D. (2006)

Substance dependence and abuse

Pietropaolo, S., Sluyter, F., & Crusio, W. E. (2014) · Cambridge University Press eBooks · doi:10.1017/cbo9781107360556.024

MDL100907

DuPre, A. (2007) · xPharm: The Comprehensive Pharmacology Reference · doi:10.1016/b978-008055232-3.62107-5

References

Crawley, J. N. (2006) · Wiley eBooks · doi:10.1002/9780470119051.refs

Animal models of attention-deficit/hyperactivity disorder: Diversity and validity

Nehme, S. B. S., Sánchez‐Sarasúa, S., Medrano, M., Bouchatta, O., Bitar, T., Alameddine, A., Galineau, L., Brunault, P., Kerekes, N., Sánchez‐Pérez, A. M., et al. (2025) · Pharmacological Reviews · doi:10.1016/j.pharmr.2025.100108

Serotonin 2A receptor antagonist treatment reduces dopamine D1 receptor-mediated rotational behavior but not l-DOPA-induced abnormal involuntary movements in the unilateral dopamine-depleted rat

Taylor, J. L., Bishop, C., Ullrich, T., Rice, K. C., & Walker, P. D. (2006) · Neuropharmacology · doi:10.1016/j.neuropharm.2005.12.004 · Cited by 43 · see citing works

The 5-HT2A receptor antagonist M100907 is more effective in counteracting NMDA antagonist- than dopamine agonist-induced hyperactivity in mice

Carlsson, M. L., Martin, P., Nilsson, M., Sorensen, S. M., Carlsson, A., Waters, N., & Waters, N. (1999) · Journal of Neural Transmission · doi:10.1007/s007020050144 · Cited by 78 · see citing works

Acute and repeated administration of the selective 5‐HT2A receptor antagonist M100907 significantly alters the activity of midbrain dopamine neurons: An in vivo electrophysiological study

Minabe, Y., Hashimoto, K., Watanabe, K., & Ashby, C. R. (2001) · Synapse · doi:10.1002/syn.1031 · Cited by 27 · see citing works

The Selective 5-HT2A Receptor Antagonist M100907 Enhances Antidepressant-Like Behavioral Effects of the SSRI Fluoxetine

Marek, G. J., Martín‐Ruiz, R., Abo, A., & Artigas, F. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300762 · Cited by 119 · see citing works

The Effects of M100907 in Pharmacological and Developmental Animal Models of Prepulse Inhibition Deficits in Schizophrenia

Geyer, M. A. (1999) · Neuropsychopharmacology · doi:10.1016/s0893-133x(99)00123-2 · Cited by 28 · see citing works